Skip to content
Peptide research

PGPIPN

Category
Specialized Research
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A casein-derived hexapeptide sold as an immune modulator, said to boost macrophage activity and calm inflammation through mechanisms whose receptor targets remain unconfirmed. Anti-cancer, liver-protective, and chemo-synergy claims rest on low-confidence or speculative animal and cell data. No human trials exist, there is no safety data, and immune stimulation is a theoretical concern in autoimmune disease. Not an approved drug in the US; supply consists of unregulated products sold online.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Anti-ovarian cancer activity (direct tumor suppression)

    Low

    Inhibited ovarian cancer cells and reduced tumor growth in mice; no human trials yet.

  • Inhibition of cancer cell invasion and migration

    Speculative

    Blocked cancer cell invasion and migration in lab-dish studies only, no animal model tested.

  • Synergy with cisplatin (chemosensitization)

    Speculative

    Increased cisplatin sensitivity in resistant ovarian cancer cells, single lab-dish study only.

Evidence limits

Evidence Level
Preclinical

All published PGPIPN research consists of in vitro cell culture experiments and in vivo mouse model studies. The peptide has been tested against human ovarian cancer cell lines (SKOV3, COC1, and their cisplatin-resistant variants) and primary ovarian cancer cells from over 40 patients, as well as in xenograft nude mouse tumor models and Kunming mouse liver disease models. There are no human pharmacokinetic, safety, efficacy, or dose-finding studies. The original immunomodulation work from the 1980s was also entirely in vitro/animal. The consistent results across multiple independent cell lines and primary patient samples are encouraging, but human translation remains untested.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No human safety data exists

    High
  • No standardized pharmaceutical-grade product available

    High
  • Potential immunostimulatory effects may be contraindicated in autoimmune conditions

    Theoretical
  • Dairy allergen origin

    Low
  • Unknown effects on healthy tissue at high systemic concentrations

    Moderate
  • Potential interaction with cancer treatment protocols

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.